Influence of IFN-gamma and its receptors in human breast cancer

García‐Tuñón, Ignacio; Ricote, Mónica; A, Antonio Ruiz; Fraile, Benito; Paniagua, Ricardo; Royuela, Mar

doi:10.1186/1471-2407-7-158

Cited by 45 publications

(34 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IFN-g receptors are expressed on human breast cancer cells 7,8 and we similarly demonstrate that IFNg-R1 is expressed on a syngeneic murine tumor cell line (Fig. 3A).…”

Section: Body Aim 1 To Identify Putative Class II Epitopes Derivedsupporting

confidence: 74%

Development of a Vaccine Targeting Triple-Negative Breast Cancer

Cecil¹

2012

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

show abstract

“…IFN-g receptors are expressed on human breast cancer cells 7,8 and we similarly demonstrate that IFNg-R1 is expressed on a syngeneic murine tumor cell line (Fig. 3A).…”

Section: Body Aim 1 To Identify Putative Class II Epitopes Derivedsupporting

confidence: 74%

Development of a Vaccine Targeting Triple-Negative Breast Cancer

Cecil¹

2012

View full text Add to dashboard Cite

show abstract

“…Using human-specific molecular tools, both type I (α, β) and II (ɣ) IFNs were detected in tumor cells in response to treatment. Since breast cancer cells have been shown to express IFN receptors [3], these observations suggested that activation of the IFN/STAT1 pathway might be induced by an autocrine/paracrine mechanism.…”

Section: Introductionmentioning

confidence: 99%

Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents

Gaston

Cheradame

Yvonnet³

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Activation of the IFN/STAT1 pathway is closely associated with drug response and recurrence of breast cancer treated by chemotherapy. The aim of the current study was to elucidate the molecular mechanisms involved upstream and downstream of this pathway in order to identify distinct entities that might be manipulated to improve treatment efficacy. Four breast cancer cell lines (T-47D, MCF7, MDA-MB-231 and HBCx-19 established from the eponymous PDX) were treated in vitro with mafosfamide, a DNA damage inducer. In two of these cell lines (MCF7 and HBCx-19), genotoxic treatment upregulated type I IFN expression leading to paracrine activation of IFN/STAT1 signaling pathway after 6–8 days. We show that STING, a well-characterized inducer of IFN in immune cells, is rapidly triggered in MCF7 cells under genotoxic stress and forms nuclear foci that co-localize with phosphorylated IRF-3 and γH2AX. STING silencing abrogated chemotherapy-induced type I IFN production and signaling and potentiated genotoxic treatment efficacy as it promoted cell death extent and delayed cell colony regrowth. Similar results were obtained after silencing PARP12, one selected gene of the IFN/STAT1 pathway fingerprint. In summary, this study provides the first demonstration of STING activation in breast cancer cells. Our data suggest that genotoxic-induced, STING-mediated type I IFN signaling is a cell-intrinsic mechanism of breast cancer cell survival and regrowth.

show abstract

“…In spite of the decreased expression of several proteins, B1 AMCE could also up-regulates several proteins such as interferon-gamma (IFN-γ) and monokine induced by interferon-γ (Mig) which underlines its favourable criteria as anti-cancer agent. It has been discovered that IFN-γ has anti-tumoral effect as it manages to inhibit the growth of tumor cell lines including breast cancer cells by causing cell cycle arrest in the expense of p21 up-regulation as reported in previous studies [37] while in another findings, indicate that IFN-γ increases the growth inhibitory effect of tamoxifen in breast metastatic carcinomas [38]. The up-regulation of Mig in the treated group is a good indicator for B1 AMCE as anti-angiogenesis agent due to its ability to inhibit angiogenesis in vivo.…”

Section: Discussionmentioning

confidence: 99%

Anti-cancer effect of Annona Muricata Linn Leaves Crude Extract (AMCE) on breast cancer cell line

Najmuddin

Romli

Hamid

et al. 2016

BMC Complement Altern Med

121

View full text Add to dashboard Cite

BackgroundAnnona muricata Linn which comes from Annonaceae family possesses many therapeutic benefits as reported in previous studies and to no surprise, it has been used in many cultures to treat various ailments including headaches, insomnia, and rheumatism to even treating cancer. However, Annona muricata Linn obtained from different cultivation area does not necessarily offer the same therapeutic effects towards breast cancer (in regards to its bioactive compound production). In this study, anti-proliferative and anti-cancer effects of Annona muricata crude extract (AMCE) on breast cancer cell lines were evaluated.MethodsA screening of nineteen samples of Annona muricata from different location was determined by MTT assay on breast cancer cell lines (MCF-7, MDA-MB-231, and 4 T1) which revealed a varied potency (IC50) amongst them. Then, based on the IC50 profile from the anti-proliferative assay, further downward assays such as cell cycle analysis, Annexin V/FITC, AO/PI, migration, invasion, and wound healing assay were performed only with the most potent leaf aqueous extract (B1 AMCE) on 4 T1 breast cancer cell line to investigate its anti-cancer effect. Then, the in vivo anti-cancer study was conducted where mice were fed with extract after inducing the tumor. At the end of the experiment, histopathology of tumor section, tumor nitric oxide level, tumor malondialdehyde level, clonogenic assay, T cell immunophenotyping, and proteome profiler analysis were performed.ResultsAnnona muricata crude extract samples exhibited different level of cytotoxicity toward breast cancer cell lines. The selected B1 AMCE reduced the tumor’s size and weight, showed anti-metastatic features, and induced apoptosis in vitro and in vivo of the 4 T1 cells. Furthermore, it decreased the level of nitric oxide and malondialdehyde in tumor while also increased the level of white blood cell, T-cell, and natural killer cell population.ConclusionThe results suggest that, B1 AMCE is a promising candidate for cancer treatment especially in breast cancer and deserves further research as an alternative to conventional drugs while also stressed out the selection of soursop sample which plays a significant role in determining its potential therapeutic effect on cancer.Electronic supplementary materialThe online version of this article (doi:10.1186/s12906-016-1290-y) contains supplementary material, which is available to authorized users.

show abstract

Influence of IFN-gamma and its receptors in human breast cancer

Cited by 45 publications

References 28 publications

Development of a Vaccine Targeting Triple-Negative Breast Cancer

Development of a Vaccine Targeting Triple-Negative Breast Cancer

Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents

Anti-cancer effect of Annona Muricata Linn Leaves Crude Extract (AMCE) on breast cancer cell line

Contact Info

Product

Resources

About